1. Home
  2. RNTX vs AIRE Comparison

RNTX vs AIRE Comparison

Compare RNTX & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • AIRE
  • Stock Information
  • Founded
  • RNTX 2001
  • AIRE 2021
  • Country
  • RNTX United States
  • AIRE United States
  • Employees
  • RNTX N/A
  • AIRE N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • AIRE
  • Sector
  • RNTX Health Care
  • AIRE
  • Exchange
  • RNTX Nasdaq
  • AIRE Nasdaq
  • Market Cap
  • RNTX 34.6M
  • AIRE 40.7M
  • IPO Year
  • RNTX N/A
  • AIRE N/A
  • Fundamental
  • Price
  • RNTX $1.25
  • AIRE $0.44
  • Analyst Decision
  • RNTX Buy
  • AIRE Hold
  • Analyst Count
  • RNTX 2
  • AIRE 1
  • Target Price
  • RNTX $10.00
  • AIRE N/A
  • AVG Volume (30 Days)
  • RNTX 2.6M
  • AIRE 18.0M
  • Earning Date
  • RNTX 11-14-2025
  • AIRE 11-12-2025
  • Dividend Yield
  • RNTX N/A
  • AIRE N/A
  • EPS Growth
  • RNTX N/A
  • AIRE N/A
  • EPS
  • RNTX N/A
  • AIRE N/A
  • Revenue
  • RNTX N/A
  • AIRE $4,149,567.00
  • Revenue This Year
  • RNTX N/A
  • AIRE $410.32
  • Revenue Next Year
  • RNTX N/A
  • AIRE $166.28
  • P/E Ratio
  • RNTX N/A
  • AIRE N/A
  • Revenue Growth
  • RNTX N/A
  • AIRE 994.18
  • 52 Week Low
  • RNTX $1.04
  • AIRE $0.14
  • 52 Week High
  • RNTX $3.50
  • AIRE $4.49
  • Technical
  • Relative Strength Index (RSI)
  • RNTX 44.48
  • AIRE 40.70
  • Support Level
  • RNTX $1.15
  • AIRE $0.50
  • Resistance Level
  • RNTX $1.32
  • AIRE $0.65
  • Average True Range (ATR)
  • RNTX 0.20
  • AIRE 0.06
  • MACD
  • RNTX -0.04
  • AIRE -0.01
  • Stochastic Oscillator
  • RNTX 11.65
  • AIRE 3.19

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.

Share on Social Networks: